Table S1. Demographics of the whole 43 explanatory variables in kidney transplantations (grouped by severe pneumonia).
| Variables | Severe pneumonia | P value | |
|---|---|---|---|
| No (n=476) | Yes (n=43) | ||
| Preoperative variables | |||
| Age | 42.84±11.24 | 50.07±10.60 | <0.001 |
| Sex | 0.388 | ||
| Female | 143 | 10 | |
| Male | 333 | 33 | |
| Blood type | 0.928 | ||
| A | 104 | 8 | |
| B | 125 | 11 | |
| AB | 40 | 3 | |
| O | 207 | 21 | |
| Smoking | 0.634 | ||
| Yes | 14 | 2 | |
| No | 462 | 41 | |
| Hypertension | 0.866 | ||
| No | 153 | 13 | |
| Yes | 323 | 30 | |
| Diabetes | 0.022 | ||
| Yes | 50 | 10 | |
| No | 426 | 33 | |
| HBsAg | 0.037 | ||
| Positive | 47 | 9 | |
| Negative | 429 | 34 | |
| CVD | 0.544 | ||
| No | 468 | 42 | |
| Yes | 8 | 1 | |
| Dialysis type | 0.072 | ||
| No dialysis | 50 | 1 | |
| Hemodialysis | 327 | 28 | |
| Peritoneal dialysis | 99 | 14 | |
| Dialysis duration | 0.12 | ||
| No dialysis | 50 | 2 | |
| ≤1 year | 255 | 19 | |
| >1 year | 171 | 22 | |
| Previous transplantation | 0.626 | ||
| Yes | 15 | 0 | |
| No | 461 | 43 | |
| Preoperative WBC | 6.63 (5.53–7.83) | 6.80 (5.68–8.66) | 0.251 |
| Preoperative neutrophil | 4.56 (3.68–5.64) | 4.73 (4.12–6.01) | 0.167 |
| Preoperative lymphocyte | 1.32 (1.02–1.64) | 1.32 (1.01–1.89) | 0.567 |
| Preoperative platelet | 195.5 (157.5–249.5) | 202 (176–272) | 0.326 |
| Preoperative Hb | 111 (98–124) | 107 (97–123) | 0.541 |
| Preoperative glucose | 5.18 (4.72–6.00) | 5.31 (4.84–6.65) | 0.306 |
| Preoperative BUN | 21.56 (16.78–27.20) | 21.75 (17.96–27.34) | 0.931 |
| Preoperative SCr | 991 (787–1,192) | 978 (856–1,168) | 0.75 |
| Preoperative uric acid | 419.45 (334.55–497.65) | 406.5 (326.4–486.7) | 0.749 |
| Preoperative albumin | 43.8 (40.5–46.8) | 41.5 (36.3–45.5) | 0.011 |
| Preoperative Immunoglobulin | 28.2 (24.9–31.35) | 29.9 (27.0–33.5) | 0.01 |
| Preoperative inorganic phosphorus | 1.80 (1.46–2.24) | 1.75 (1.53–2.00) | 0.659 |
| Preoperative total cholesterol | 4.35 (3.72–5.19) | 4.54 (3.98–5.49) | 0.075 |
| Preoperative triglyceride | 1.43 (1.01–2.11) | 1.61 (1.13–2.66) | 0.105 |
| Preoperative HDL | 1.07 (0.87–1.32) | 0.97 (0.82–1.17) | 0.096 |
| Preoperative LDL | 2.35 (1.85–2.96) | 2.62 (1.95–3.17) | 0.146 |
| Preoperative pulmonary radioscopic inflammatory lesion (pulmonary edema excluded) | <0.001 | ||
| Yes | 41 | 17 | |
| No | 435 | 26 | |
| Donor age | 40.96±14.45 | 46.86±12.13 | 0.005 |
| Dnor sex | 0.148 | ||
| Female | 91 | 4 | |
| Male | 384 | 39 | |
| Donor kidney | 0.203 | ||
| Right | 240 | 17 | |
| Left | 235 | 26 | |
| Donor terminal SCr | 119 (77–212) | 145 (71–217) | 0.687 |
| Intra and postoperative variables | |||
| Surgery time (hours) | 3.33 (2.94–3.92) | 3.70 (3.12–4.27) | 0.027 |
| Reoperation | <0.001 | ||
| No | 466 | 36 | |
| Yes | 10 | 7 | |
| Induction | >0.999 | ||
| T-cell depletion | 423 | 39 | |
| Non-depletion | 53 | 4 | |
| rATG dose (bolus) | 6 (4–8) | 6 (6–8) | 0.056 |
| rATG dose category | 0.36 | ||
| No rATG | 53 | 4 | |
| <6 boluses | 89 | 6 | |
| 6 boluses | 199 | 15 | |
| >6 boluses | 135 | 18 | |
| Simulect | |||
| Yes | 91 | 8 | >0.999 |
| No | 385 | 35 | |
| IVIg prophylaxis | 0.638 | ||
| Yes | 65 | 4 | |
| No | 411 | 39 | |
| Ganciclovir | 0.871 | ||
| Yes | 286 | 25 | |
| No | 190 | 18 | |
| Anti-fungi drugs | 0.026 | ||
| Caspofungin | 209 | 25 | |
| Micafungin | 266 | 17 | |
| Other | 1 | 1 | |
| Alprostadil | 0.248 | ||
| No | 66 | 3 | |
| Yes | 410 | 40 | |
| Delayed graft function | 0.005 | ||
| Yes | 40 | 10 | |
| No | 436 | 33 | |
Differences test in continuous variables were analyzed using the Wilcoxon rank-sum test; differences in categorical variables were analyzed using Fisher’s exact test. WBC, white blood cell; BUN, blood urea nitrogen; CVD, cardiac vascular disease; HDL, high density lipoprotein cholesterol; LDL, low-density lipoprotein; IVIg, intravenous immunoglobulin; rATG dose, rabbit anti-human thymocyte globulin (Thymoglobulin® 25 mg/bolus), we also used ATG-F, anti-human T lymphocyte rabbit immunoglobulin (Grafalon®, 100 mg converted to rATG in two boluses) and ALG, porcine anti-human lymphocyte immunoglobulin (250 mg/bolus, converted to rATG in one bolus).